Glaucoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged between 18 and 90 years old
- People who have been diagnosed with primary open angle glaucoma (mild, moderate, or advanced stage)
- People who have healthy eyes with no eye disease
Who may not be able to join:
- People who have eye or general health conditions that are likely to affect the results of a specific eye scan called OCTA
- People who have more than a moderate level of cataracts (clouding of the eye lens)
- People who have uncontrolled eye movement (nystagmus)
- People who are unable to focus their gaze on a target during eye testing
- People who have macular degeneration beyond mild early changes
- People who have diabetic retinopathy (eye damage related to diabetes)
- People who have a type of glaucoma caused by abnormal blood vessel growth, or other non-glaucoma optic nerve conditions
- People who currently have swelling at the back of the eye (macular edema), have previously had laser treatment to the retina, or have inflammatory conditions affecting the retina or underlying eye tissue
- People who have conditions affecting the shape of the cornea (front surface of the eye), such as keratoconus, corneal ectasia, or central corneal scarring
- People who have rheumatological (joint and immune) diseases or Raynaud's phenomenon (a condition affecting blood flow to the fingers and toes)
- People who are pregnant or breastfeeding
- People who have a mental illness or alcohol addiction
- People who have pre-existing bladder symptoms, heart disease, or a sleep disorder
- People whose glasses or contact lens prescription is stronger than a certain level (confirm with trial site)
- People who may have a tolerance to caffeine from drinking more than one cup of coffee per day
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: M. Reza Razeghinejad, MD, Wills Eye Hospital
Phone: 215-928-7023
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Blood flow change in back of eye before and after caffeine
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.